FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR

Abstract

Provided herein is a free base crystalline form of a complement component 5a receptor having the formula of Compound 1Also provided herein are pharmaceutical compositions and methods of treatment using the crystalline free base form of Compound 1 described herein.

1 . A pharmaceutical composition for oral use prepared using a free base crystalline form of Compound 1 
       
         
           
           
               
               
           
         
       
       which is substantially free of other forms of Compound 1. 
     
     
         2 . The pharmaceutical composition of  claim 1 , characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.1, 8.4, 14.1, 16.9, and 19.0 degrees 2θ (±0.2 degrees 2θ). 
     
     
         3 . The pharmaceutical composition of  claim 2 , further characterized by XRPD peaks at 12.4, 15.2, 16.1, 24.4, and 24.7 degrees 2θ (±0.2 degrees 2θ) 
     
     
         4 . The pharmaceutical composition of  claim 1 , characterized by an X-ray powder diffraction pattern substantially in accordance with  FIG.  1   . 
     
     
         5 . The pharmaceutical composition of  claim 1 , further characterized by a differential scanning calorimetry thermogram (DSC) comprising an endothermic peak at around 216° C. 
     
     
         6 . The pharmaceutical composition of  claim 1 , further characterized by a melting point onset of about 213° C. as determined by differential scanning calorimetry thermogram (DSC). 
     
     
         7 . The pharmaceutical composition of  claim 1 , further characterized by a DSC substantially in accordance with  FIG.  2   . 
     
     
         8 .- 28 . (canceled)